Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7272MR)

This product GTTS-WQ7272MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7272MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ482MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ13402MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ11075MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ3331MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ15836MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ4667MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ355MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ4614MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW